Tadalafil Tablet, Film Coated
Product Images NDC 72303-0825

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 72303-0825). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hec Pharm Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

A0f6fc35 4b63 38bf E053 2995a90a8be2

Label for Tadalafil 2.5 mg film-coated tablets, USP by HEC Pharm USA Inc. The oral prescription drug is supplied in a bottle of 30 tablets. The label includes dosing guidance, storage instructions, and warnings, noting the tablets should not be split and the entire dose taken. Manufactured by Sunshine Lake Pharma Co., China.*

FDA Label Image

Logo0001-01 (01)

FDA Label Image

Logo0001-01 (02)

FDA Label Image

Logo0001-01 (03)

FDA Label Image

Logo0001-01 (07)

FDA Label Image

10mg-30 (Tadalafil 10mg 30ct 033 00)

Packaging label for Tadalafil tablets USP 10 mg by HEC Pharm USA Inc. The label states the dosage form as film-coated tablets with 30 tablets per container. Storage instructions and warnings are provided, including keeping out of reach of children and dispensing in a tight container. The label includes manufacturer information and a barcode.*

FDA Label Image

20mg-30 (Tadalafil 20mg 30ct 034 00)

Label for Tadalafil tablets, USP 20 mg, oral film-coated tablets. The label states the NDC 72303-0825-1 and indicates a quantity of 30 tablets. It includes storage instructions, manufacturer details (HEC Pharm USA Inc. and Sunshine Lake Pharma Co., Ltd.), and cautions that tablets should not be split with the entire dose taken. The label features the HEC logo and barcode.*

FDA Label Image

20mg-60 (Tadalafil 20mg 60ct 034 00)

Label for Tadalafil tablets USP, 20 mg oral film-coated tablets by HEC Pharm USA Inc. The package contains 60 tablets. The label includes storage instructions, a warning to keep out of reach of children, and states tablets should not be split. Manufactured by Sunshine Lake Pharma Co., Ltd.*

FDA Label Image

5mg-30 (Tadalafil 2point5mg 30ct 031 00)

Label for Tadalafil tablets, USP 2.5 mg by HEC Pharm USA Inc. The film-coated tablets are available in a 30-count package. The label includes dosage guidance, storage instructions (20°C to 25°C), and warnings such as keeping out of children's reach. Manufactured by Sunshine Lake Pharma Co., Ltd.*

FDA Label Image

5mg-30 (Tadalafil 5mg 30ct 032 00)

The label is for Tadalafil tablets, USP, 5 mg strength, a human prescription drug by HEC Pharm USA Inc. It states the dosage form as film-coated tablets with a package count of 30 tablets. The label includes storage instructions, warnings, manufacturer information, and cautions that tablets should not be split and the entire dose should be taken. The NDC number 72303-0823-1 and a barcode are visible.*

FDA Label Image

Chemical Structure (Tadalafil Uspi F001 Structure V1)

Chemical structure of the active ingredient Tadalafil. The diagram shows the molecular framework, including rings and functional groups characteristic of Tadalafil.*

FDA Label Image

Figure (Tadalafil Uspi F001 V2)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following 5 consecutive days. The y-axis represents plasma concentration up to 500 µg/L, and the x-axis shows time up to 120 hours. Data points include error bars indicating variability.*

FDA Label Image

Figure (Tadalafil Uspi F002 V1)

A set of four line graphs depicting changes in blood pressure measurements over time. The graphs show the difference in systolic and diastolic blood pressure for standing and supine positions, comparing Tadalafil versus placebo over a 96-hour period. Error bars indicate variability at each time point.*

FDA Label Image

Figure (Tadalafil Uspi F003 V1)

This figure includes two line graphs showing the effects of Tadalafil 20 mg combined with doxazosin 8 mg versus placebo with doxazosin 8 mg on standing and supine systolic blood pressure (BP) over time post-dose in hours. The top graph plots standing systolic BP change, while the bottom one plots supine systolic BP change, both measured in mmHg.*

FDA Label Image

Figure (Tadalafil Uspi F004 V1)

A line graph depicting systolic blood pressure (mmHg) changes over 12 hours following administration of tadalafil or placebo combined with doxazosin. The x-axis represents time after administration, and the y-axis shows systolic blood pressure in mmHg. Four data series compare tadalafil dosed at 20 mg at 08:00 and 20:00 with placebo alongside 8 mg daily doxazosin at 08:00.*

FDA Label Image

Figure 5 (Tadalafil Uspi F005 V1)

Line graph comparing change from baseline in IPSS Total Score over 12 weeks between Tadalafil 5 mg and placebo groups. The x-axis represents duration of treatment in weeks, from 0 to 12, and the y-axis shows change in IPSS Total Score, ranging from 0 to -6. The Tadalafil group shows a greater decrease from baseline than placebo, with a statistically significant difference at 12 weeks (p<0.01).*

FDA Label Image

Figure 6 (Tadalafil Uspi F006 V1)

A line graph showing change from baseline in IPSS Total Score over 12 weeks of treatment, comparing Tadalafil 5 mg with placebo. The x-axis represents duration of treatment in weeks, and the y-axis shows the change from baseline. The graph indicates greater score reduction with Tadalafil 5 mg versus placebo, with statistical significance (*) at weeks 4 and 12.*

FDA Label Image

Figure 7 (Tadalafil Uspi F007 V2)

A line graph showing Least Squares Mean Change from Baseline over Weeks of Therapy (0 to 26 weeks) comparing Tadalafil/Finasteride versus Placebo/Finasteride. The plot depicts a steeper decline for Tadalafil/Finasteride with statistical notation for significance at weeks 4, 12, and 26.*

FDA Label Image

Figure 8 (Tadalafil Uspi F008 V1)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks of treatment between Tadalafil 5 mg and placebo. The x-axis represents the duration of treatment in weeks, and the y-axis shows the change from baseline score. The Tadalafil 5 mg group shows a greater decrease in score than placebo, with statistical significance indicated at 12 weeks (p < 0.01).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.